Jung, Jaeyong Sung, Jeong Soo Kwon, Soonil Bae, Hyung Eun Kang, Min-Jung Jose, Joachim Lee, Misu Pyun, Jae-Chul 2024-10-02T09:30:35Z 2024-10-02T09:30:35Z 2024-10-02 2024-11 2632-8682 https://pubs.kist.re.kr/handle/201004/150695 Fv-antibodies targeting the proprotein convertase (PPC) region of the SARS-CoV-2 spike protein (SP) were screened from an Fv-antibody library to inhibit SARS-CoV-2 infection. Two selected Fv-antibodies were expressed as soluble recombinant proteins, and their binding affinities were assessed using a surface plasmon resonance biosensor. The binding regions of these Fv-antibodies corresponded to the cleavage sites of furin (S1/S2) and transmembrane serine protease 2 (TMPRSS2, S2 '). The neutralizing activities of the two Fv-antibodies were demonstrated using a cell-based infection assay with pseudo-viruses carrying the SP of four different SARS-CoV-2 variants: wild-type (D614), delta (B.1.617.2), omicron (BA.2), and omicron (BA.4/5). Fv-antibodies targeting the PPC region of SARS-CoV-2 to prevent infection, screened from an Fv-antibody library (displayed on outer membrane of E. coli cell). English Royal Society of Chemistry Preventing SARS-CoV-2 infection using Fv-antibodies targeting the proprotein convertase (PPC) cleavage site Article 10.1039/d4md00552j 1 RSC Medicinal Chemistry, v.15, no.11, pp.3704 - 3710 RSC Medicinal Chemistry 15 11 3704 3710 N scie scopus 001310650600001 2-s2.0-85204392678 Biochemistry & Molecular Biology Chemistry, Medicinal Biochemistry & Molecular Biology Pharmacology & Pharmacy Article; Early Access